Hodgkin lymphoma: great progress with room for improvement

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-03-10 DOI:10.1038/s41571-025-01012-2

Paul J. Bröckelmann

引用次数: 0

Abstract

First-line treatment of advanced-stage classic Hodgkin lymphoma (HL) has successfully entered the era of targeted agents based on results from the phase III German Hodgkin Study Group HD21 and US intergroup S1826 trials. Although these trials bring about important advances, many uncertainties remain and the outcomes of all patients with HL can be further improved.

Abstract Image

查看原文本刊更多论文

霍奇金淋巴瘤：进展很大，但仍有改善的余地

根据德国霍奇金研究组 HD21 和美国间组 S1826 III 期试验的结果，晚期典型霍奇金淋巴瘤（HL）的一线治疗已成功进入靶向药物时代。尽管这些试验取得了重要进展，但仍存在许多不确定因素，所有霍奇金淋巴瘤患者的预后都有待进一步改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.